Wide Ranks

KALA

KALA BIO, Inc.

6.65

Top Statistics
Market Cap 30 M Forward PE -1.10 Revenue Growth 0.00 %
Current Ratio 3.07 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.3730 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 54 M Total Cash Per Share 11.76 Total Debt 36 M
Total Debt To Equity 268.29 Current Ratio 3.07 Book Value Per Share 2.72
All Measures
Short Ratio 191.00 % Message Board Id finmb_83652421 Fax 781 642 0399
Shares Short Prior Month 29892 Return On Equity -2.48 City Arlington
Uuid 06a09f76-df06-3807-bce5-79032313c0fe Previous Close 6.55 First Trade Date Epoch Utc 1 B
Book Value 2.72 Beta -2.14 Total Debt 36 M
Volume 83946 Price To Book 2.45 Last Split Date 1 B
Fifty Two Week Low 4.21 Total Cash Per Share 11.76 Shares Short Previous Month Date 1 B
Target Median Price 15.00 Max Age 86400 Recommendation Mean 1.50
Sand P52 Week Change 0.3133 Target Mean Price 15.00 Net Income To Common -38717000
Short Percent Of Float 0.0085 Implied Shares Outstanding 4 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 36440 Average Volume10days 36440
Total Cash 54 M Next Fiscal Year End 1 B Held Percent Insiders 0.0514
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 6.55 Target Low Price 15.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 6.13 Open 6.45 Free Cashflow -20511750
State MA Dividend Yield 0.00 % Return On Assets -0.4025
Time Zone Short Name EST Trailing Eps -11.67 Day Low 6.25
Address1 1167 Massachusetts Avenue Shares Outstanding 4 M Price Hint 2
Target High Price 15.00 Website https://www.kalarx.com 52 Week Change 0.0992
Average Volume 22901 Forward Eps -6.67 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 283.50 % Last Split Factor 1:50
Regular Market Day High 6.95 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 268.29 Fifty Two Week High 10.97 Day High 6.95
Shares Short 37467 Regular Market Open 6.45 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0081
Operating Cashflow -30707000 Currency USD Time Zone Full Name America/New_York
Market Cap 30 M Is_nasdaq_100 False Zip 02476
Quote Type EQUITY Industry Biotechnology Long Name KALA BIO, Inc.
Regular Market Day Low 6.25 Held Percent Institutions 0.4813 Current Price 6.65
Enterprise To Ebitda -0.3730 Financial Currency USD Current Ratio 3.07
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 2 M Two Hundred Day Average 6.58 Enterprise Value 15 M
Forward PE -1.10 Regular Market Volume 83946 Ebitda -40978000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States.

The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.

Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.

The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.

KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.